Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;52(8):1216-1227.
doi: 10.1002/eji.202149358. Epub 2022 Jul 25.

Regulatory T-cell development in the tumor microenvironment

Kota Itahashi  1 , Takuma Irie  1 , Hiroyoshi Nishikawa  1   2
Affiliations
Free article
Review

Regulatory T-cell development in the tumor microenvironment

Kota Itahashi et al. Eur J Immunol. 2022 Aug.
Free article

Abstract

Regulatory T (Treg) cells are required for maintaining self-tolerance and preventing the development of autoimmune diseases. However, Treg cells are abundant in tumors and suppress antitumor immunity, contributing to tumor development and growth. Thus, the selective deletion of tumor-infiltrating Treg cells is important for successful Treg cell-targeted therapies, providing effective antitumor immunity without inducing deleterious autoimmune disorders. Advancements in sequencing technologies have exposed the diversity and heterogeneity of human Treg cells during activation and differentiation, further emphasizing the importance of understanding tumor-infiltrating Treg cells for the development of Treg cell-targeted therapies. This review provides an overview of the classification and function of Treg cells and summarizes recent knowledge on the activation and differentiation of Treg cells in the tumor microenvironment.

Keywords: immunotherapy; regulatory T cells; tumor microenvironment.

PubMed Disclaimer

References

    1. Rabinovich, G. A., Gabrilovich, D. and Sotomayor, E. M., Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007. 25: 267-296.
    1. Gabrilovich, D. I., Myeloid-Derived Suppressor Cells. Cancer Immunol Res 2017. 5: 3-8.
    1. Pathria, P., Louis, T. L. and Varner, J. A., Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol 2019. 40: 310-327.
    1. Pardoll, D. M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012. 12: 252-264.
    1. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D. et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012. 366: 2443-2454.

Publication types

LinkOut - more resources